about us
Airway Therapeutics was created in 2011 as a spin-out of Cincinnati Children’s Hospital Medical Center.
about us
BPD
Bronchopulmonary dysplasia (BPD) is a lung disease affecting preterm babies.
BPD
AT-100
Airway Therapeutics' protein replacement therapy targeting BPD.
AT-100
news
Our latest news, scientific publications and media coverage.
news
AIRWAY THERAPEUTICS
Created in 2011 as a spin-out of Cincinnati Children’s Hospital Medical Center (CCHMC), Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics. Airway Therapeutics is developing AT-100 (rhSP-D), a product targeting bronchopulmonary dysplasia in newborns.
WHAT IS BPD?
Bronchopulmonary dysplasia is a developmental disorder in premature neonates that leads to an arrested lung development, which in turn results in chronic lung disease. Today, current therapies lack critical proteins necessary to prevent the onset of BPD.
AT-100
AT-100 is a recombinant form of human surfactant protein-D (rhSP-D). SP-D, absent from current therapies, is a normal protein component of lung surfactant that performs three critical roles in maintaining healthy lung function.
the latest news
Airway Therapeutics Closes $15.5 Million Series C Financing to Advance Preclinical and Clinical Research and Development Programs to Prevent and Treat Serious Respiratory Diseases
Airway Therapeutics Announces Appointment of Chief Medical Officer
Airway Therapeutics Closes $11M Series B Round of Financing
Airway Therapeutics, LLC Obtains License on Glycotope Cell Line
CONTACT
For members of the scientific/medical and investment communities,
contact us at the link below by filling out our inquiry form.
